FierceBiotechOriginal article
{"a":[{"_":"GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck","$":{"href":"/biotech/gsks-adc-lays-down-marker-lung-cancer-scrap-merck-co","hreflang":"en"}}]}
Phase 3positiverisvutatug rezetecanPositive
AI Analysis
Summary
GSK's Hansoh-partnered ADC risvutatug rezetecan achieved median overall survival of 18.5 months in a Phase 3 lung cancer trial, positioning it as a competitive threat to Amgen and Merck in the field.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Median overall survival of 18.5 months achieved
Importance:7/10
Sentiment:
0.70
ADCantibody-drug conjugatelung cancerPhase 3clinical trialoncology
Read the original article
Published by FierceBiotech on September 11, 2026 4:54 AM